<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138472</url>
  </required_header>
  <id_info>
    <org_study_id>3</org_study_id>
    <nct_id>NCT04138472</nct_id>
  </id_info>
  <brief_title>Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy</brief_title>
  <official_title>Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sana Urooj</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dow University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dow University of Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response
      To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Direct laryngoscopy and intubation are painful stimulus that activates sympathoadrenal
      discharge which results in intense cardiovascular reflex i.e. tachycardia and hypertension.
      In this study we will compare effects of intravenous dexmedetomidine, fentanyl and lidocaine
      for attenuation of these reflexes in patient undergoing laproscopic cholecystectomy. how
      these agents will effect hemodynamic response during pneumoperitoneum. Tertiary objective
      will be to observe sedation, perioperative complications and recovery in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Anticipated">February 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized control trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients do not know about the interventions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>systolic blood pressure</measure>
    <time_frame>at induction</time_frame>
    <description>hermodynamic response (Top number will be assessed of blood pressure)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>at induction</time_frame>
    <description>hermodynamic response (bottom number will be assessed of blood pressure)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mean atrial pressure</measure>
    <time_frame>at induction</time_frame>
    <description>Hemodynamic responses (average blood pressure in an individual during a single cardiac cycle)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>at induction</time_frame>
    <description>Hemodynamic responses (average heart rate beats a minute)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen saturation (SpO2)</measure>
    <time_frame>at induction</time_frame>
    <description>Hemodynamic responses) (arterial oxy-hemoglobin saturation is measured non-invasively by a finger pulse oximeter or handheld pulse oximeter,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation assessment</measure>
    <time_frame>at 10 minutes post operative</time_frame>
    <description>Ramsey score use for sedation, it consist of 1-6 where 6 indicates worst(no response) and 6 indicates good response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery assessment</measure>
    <time_frame>at 10 minutes post operatively</time_frame>
    <description>Aldret score use for recovery assessment, it consist of 0-10 point where 0 indicates worst(no response) and 10 indicates good response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1 week Post-operative(Operation -discharge)</time_frame>
    <description>Cough, Laryngospasm, Bradycardia, Regugitation, PONV, Hypertention, Hypotension</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Laparoscopic Cholecystectomy</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A patients receive intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B receives intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C patients receives intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl</intervention_name>
    <description>intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.</description>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA-I and ll patients

          -  Male and female patient of age 20-70 years.

          -  Undergoing Elective surgery

          -  Intubation by skilled anesthetist of at least 2 years' experience

          -  Intubation not more than 45 seconds

        Exclusion Criteria:

          -  Patients with uncontrolled DM, HTN, IHD, endocrine or autonomic dysfunction

          -  Pregnant and lactating females

          -  Short thick neck with anticipated difficult intubation

          -  Any sort of obstructive restrictive or reactive airway disease

          -  Patient allergic to any of the study medications.

          -  Obese patients, Narcotic addicts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sana Urooj, FCPS</last_name>
    <phone>+923333515690</phone>
    <email>dr.sanaurooj@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sana Urooj</last_name>
    <phone>03333515690</phone>
    <email>dr.sanaurooj@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DUHS, Civil hospital Karachi (CHK)</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>75520</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0333351560</phone>
      <email>dr.sanaurooj@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Sana Urooj, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanya Jawed, FCPS-res</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DUHS, Civil hospital Karachi (CHK)</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>75520</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dow University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Sana Urooj</investigator_full_name>
    <investigator_title>SUrooj</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Fentanyl</keyword>
  <keyword>Lignocaine</keyword>
  <keyword>Laryngoscopy</keyword>
  <keyword>Hemodynamic Response</keyword>
  <keyword>Laparoscopic Cholecystectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

